Petri dish

Promising news on the immunotherapies front! Impressive results have been published last week regarding two new immunotherapies, pembrolizumab and nivolumab, treating patients diagnosed with melanoma, non-small cell lung cancer and renal cancer.

Data from phase 3 trials for the breakthrough immunotherapies pembrolizumab and nivolumab have shown exiting results for the treatment of melanoma, non-small cell lung cancer and renal cancer. The data was presented last week at the convention of the American Society of Clinical Oncology (ASCO) 2015.

Many media have reported about these results, a short overview can be found below: